SML3650
CTPI-2
≥98% (HPLC)
别名:
2-(4-Chloro-3-nitrobenzenesulfonamido)benzoic acid, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]benzoic acid, CTPI 2, CTPI2
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C13H9ClN2O6S
化学文摘社编号:
分子量:
356.74
UNSPSC Code:
12352200
NACRES:
NA.25
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[S](=O)(=O)(Nc2c(cccc2)C(=O)O)c1cc(c(cc1)Cl)[N+](=O)[O-]
InChI
1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)
InChI key
NJTHPOSQGFJTDP-UHFFFAOYSA-N
Biochem/physiol Actions
CTPI-2 is a selective mitochondrial citrate transporter (SLC25A1) inhibitor that displays H1299 anti-proliferation activity in a SLC25A1-dependent manner (IC50 <10 μM). When compared with CTPI-1, CTPI-2 exhibits 20-fold higher target affinity (hSLC25A1 KD = 3.5 μM vs. 63.6 μM, respectively) and is ~1000-fold more potent against H1299 sphere-forming capacity. CTPI-2 inhibits mitochondrial respiration and formation of patient NSCLC tumors-derived CSCs spheres in cultures (10-50 μM), as well as suppresses the growth of patent-derived NSCLC exnografts in mice in vivo (28 mg/kg q.o.d. i.p.).
Selective mitochondrial citrate transporter (SLC25A1) inhibitor with anti-cancer efficacy in cultures and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable